Modulation of vasoactivity and platelet aggregation by selective 5-HT receptor antagonism in humans

Journal of Cardiovascular Pharmacology

Volumn 58, Issue 6, 2011, Pages 575-580

  Moerland, Matthijs ^a   Kemme, Michiel ^a   Dijkmans, Anneke ^a   Bergougnan, Luc ^b   Burggraaf, Jacobus ^a  

^a CENTRE FOR HUMAN DRUG RESEARCH   (Netherlands)

^b SANOFI   (France)

Author keywords

platelet aggregation; serotonin; SL65.0472 00; sumatriptan; vasoactivity; vasoconstriction

Indexed keywords

PLACEBO; SEROTONIN; SEROTONIN 1B ANTAGONIST; SEROTONIN 1B RECEPTOR; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; SL 65 0472 00; SUMATRIPTAN; UNCLASSIFIED DRUG;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG MECHANISM; FOREARM BLOOD FLOW; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE AGGREGATION; TIME TO MAXIMUM PLASMA CONCENTRATION; VASOCONSTRICTION;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FOREARM; HUMANS; MALE; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; PLETHYSMOGRAPHY; QUINOLINES; RECEPTOR, SEROTONIN, 5-HT1B; RECEPTOR, SEROTONIN, 5-HT2A; SEROTONIN; SEROTONIN ANTAGONISTS; SUMATRIPTAN; TIME FACTORS; VASOCONSTRICTION; YOUNG ADULT;

EID: 83155175327     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31822f6b8d     Document Type: Article

References (29)

1. Bruning TA, Chang PC, Blauw GJ, et al. Interactions between serotonin and endogenous and exogenous noradrenaline in the human forearm. Blood Press. 1994;3:309-318. (Pubitemid 24325853)
2. Nugent AG, McGurk C, Johnston GD. Forearm vascular responses to serotonin are not mediated by products of cyclooxygenase. Br J Clin Pharmacol. 1996;41:241-243. (Pubitemid 26079184)
3. Kemme MJ, Burggraaf J, Schoemaker RC, et al. No evidence for functional involvement of 5-HT2B receptors in serotonin-induced vasodilatation in the human forearm. J Cardiovasc Pharmacol. 2000;36: 699-703.
4. Kadokami T, Egashira K, Kuwata K, et al. Altered serotonin receptor subtypes mediate coronary microvascular hyperreactivity in pigs with chronic inhibition of nitric oxide synthesis. Circulation. 1996;94: 182-189. (Pubitemid 26240555)
5. Feletou M, Dellazuana O, Duhault J. Serotoninergic receptor subtype in coronary artery smooth muscle from young and atherosclerotic rabbit. J Pharmacol Exp Ther. 1994;268:124-132. (Pubitemid 24039078)
6. Janiak P, Lainee P, Grataloup Y, et al. Serotonin receptor blockade improves distal perfusion after lower limb ischemia in the fatty Zucker rat. Cardiovasc Res. 2002;56:293-302. (Pubitemid 35223500)
7. McCort G, Hoornaert C, Aletru M, et al. Synthesis and SAR of 3- and 4-substituted quinolin-2-ones: Discovery of mixed 5-HT(1B)/5-HT(2A) receptor antagonists. Bioorg Med Chem. 2001;9:2129-2137. (Pubitemid 32739200)
8. Galzin AM, Delahaye M, Hoornaert C, et al. Effects of SL 65.0472, a novel 5-HT receptor antagonist, on 5-HT receptor mediated vascular contraction. Eur J Pharmacol. 2000;404:361-368.
9. OConnor SE, Grosset A, La Rochelle CD, et al. Cardiovascular effects of SL65.0472, a 5-HT receptor antagonist. Eur J Pharmacol. 2001;414: 259-269. (Pubitemid 32181894)
10. Berry CN, Lorrain J, Lochot S, et al. Antiplatelet and antithrombotic activity of SL65.0472, a mixed 5-HT1B/5-HT2A receptor antagonist. Thromb Haemost. 2001;85:521-528. (Pubitemid 32233029)
11. Barbe F, Gautier E, Bidouard JP, et al. SL65.0472 blocks 5-hydroxytryptamine- induced vasoconstriction in a dog hindlimb ischemia model. Eur J Pharmacol. 2003;474:117-120. (Pubitemid 37289152)
12. Guilbert F, Lainee P, Dubreuil B, et al. Serotonin aggravates exerciseinduced cardiac ischemia in the dog: effect of serotonin receptor antagonists. Eur J Pharmacol. 2004;497:55-63. (Pubitemid 39092428)
13. Moerland M, Kemme M, van der Linden M, et al. Measurement of collagen- and serotonin-induced platelet aggregation in whole blood. Exp Rev Clin Pharmacol. 2010;3:177-182.
14. Terron JA. The relaxant 5-HT receptor in the dog coronary artery smooth muscle: Pharmacological resemblance to the cloned 5-HT7 receptor subtype. Br J Pharmacol. 1996;118:1421-1428. (Pubitemid 26248794)
15. Chester AH, Martin GR, Bodelsson M, et al. 5-Hydroxytryptamine receptor profile in healthy and diseased human epicardial coronary arteries. Cardiovasc Res. 1990;24:932-937. (Pubitemid 20384704)
16. Bax WA, Renzenbrink GJ, Heuven-Nolsen D, et al. 5-HT receptors mediating contractions of the isolated human coronary artery. Eur J Pharmacol. 1993;239:203-210. (Pubitemid 23240160)
17. Kaumann AJ, Frenken M, Posival H, et al. Variable participation of 5-HT1-like receptors and 5-HT2 receptors in serotonin-induced contraction of human isolated coronary arteries. 5-HT1-like receptors resemble cloned 5-HT1D beta receptors. Circulation. 1994;90:1141-1153.
18. Hannon J, Hoyer D. Molecular biology of 5-HT receptors. Behav Brain Res. 2008;195:198-213.
19. Razzaque Z, Heald MA, Pickard JD, et al. Vasoconstriction in human isolated middle meningeal arteries: Determining the contribution of 5-HT1B- and 5-HT1F-receptor activation. Br J Clin Pharmacol. 1999; 47:75-82. (Pubitemid 29043168)
20. Munoz-Islas E, Lozano-Cuenca J, Gonzalez-Hernandez A, et al. Spinal sumatriptan inhibits capsaicin-induced canine external carotid vasodilatation via 5-HT1B rather than 5-HT1D receptors. Eur J Pharmacol. 2009;615:133-138.
21. van Es NM, Bruning TA, Camps J, et al. Assessment of peripheral vascular effects of antimigraine drugs in humans. Cephalalgia. 1995;15:288-291.
22. Li N, Wallen NH, Ladjevardi M, et al. Effects of serotonin on platelet activation in whole blood. Blood Coagul Fibrinolysis. 1997;8: 517-523. (Pubitemid 28023394)
23. Maayani S, Schwarz T, Craddock-Royal B, et al. Activation of the alpha (2A)-adrenoceptor mediates deceleration of the deaggregation component of the response to ADP or 5-HT in human platelets in vitro. Platelets. 2001;12:359-375. (Pubitemid 32896893)
24. Torr S, Noble MI, Folts JD. Inhibition of acute platelet thrombosis formation in stenosed canine coronary arteries by specific serotonin 5HT2 receptor antagonist ritanserin. Cardiovasc Res. 1990;24:465-470. (Pubitemid 20188769)
25. Hara H, Kitajima A, Shimada H, et al. Antithrombotic effect of MCI- 9042, a new antiplatelet agent on experimental thrombosis models. Thromb Haemost. 1991;66:484-488.
26. Cohen ML, Robertson DW, Bloomquist WE, et al. LY215840, a potent 5-hydroxytryptamine (5-HT)2 receptor antagonist, blocks vascular and platelet 5-HT2 receptors and delays occlusion in a rabbit model of thrombosis. J Pharmacol Exp Ther. 1992;261:202-208.
27. Tanaka T, Morishima Y, Watanabe K, et al. Combined effect of the 5-HT2 receptor antagonist DV-7028 and aspirin or heparin on coronary cyclic flow reductions in dogs. Cardiovasc Res. 1993;27: 1374-1379. (Pubitemid 23250923)
28. Herbert JM, Bernat A, Barthelemy G, et al. Antithrombotic activity of SR 46349, a novel, potent and selective 5-HT2 receptor antagonist. Thromb Haemost. 1993;69:262-267. (Pubitemid 23069005)
29. Moerland et al J Cardiovasc Pharmacol Volume 58, Number 6, December 2011